New Delhi, May 12 — Morepen Laboratories Ltd reported a 31% year-on-year decline in consolidated net profit for the March quarter, even as full-year profits surged and the company announced strategic expansion plans.
Q4 Results: Profit Drops Despite Revenue Growth
In the January–March 2025 quarter, Morepen posted a consolidated net profit of Rs 20 crore, compared to Rs 29 crore in the same period last year. However, total income rose to Rs 470 crore, up from Rs 427 crore a year earlier, according to a regulatory filing.FY25 Performance: Full-Year Profit Jumps
For the financial year ended March 31, 2025, the company reported a consolidated net profit of Rs 118 crore, marking a rise from Rs 97 crore in FY24. Annual total income grew to Rs 1,830 crore, compared to Rs 1,704 crorein the previous year.Dividend and Strategic Expansion
The board of directors approved a final dividend of Rs 0.20 per share of face value Rs 2 each for FY25.In a notable development, the board also approved a proposal for Morepen Medipath Ltd, a subsidiary, to incorporate a wholly-owned unit in Dubai, UAE. The expansion aims to bolster Morepen’s presence in both B2C and B2B segments, especially in the medical device business.